Details of the Drug

General Information of Drug (ID: DMTHR4U)

Drug Name
ASM8
Indication
Disease Entry ICD 11 Status REF
Allergic asthma CA23.0 Phase 2 [1]
Drug Type
Antisense drug
Cross-matching ID
TTD ID
D0L3IL

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
CCR3 messenger RNA (CCR3 mRNA) TTU3Y87 CCR3_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Allergic asthma
ICD Disease Classification CA23.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
CCR3 messenger RNA (CCR3 mRNA) DTT CCR3 3.77E-02 -0.01 -0.04
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT01380236) A Single Blind Study to Evaluate the Safety, Tolerability and Explore the Efficacy of 8.0 mg ASM8 Inhaled Daily for 14 Days in Severe Asthma. U.S. National Institutesof Health.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 60).